Loading...
•
Dec 31, 2021
NeoGenomics Q4 2021 Earnings Report
NeoGenomics experienced flat revenue year-over-year, excluding COVID-19 PCR testing revenue, consolidated revenue increased 7%.
Key Takeaways
NeoGenomics, Inc. reported fourth quarter consolidated revenue of $126 million, which was flat compared to the fourth quarter of 2020. Excluding COVID-19 PCR testing, consolidated revenue increased year-over-year by 7%. The company's net loss for the quarter was $42 million, compared to net income of $15 million in the fourth quarter of 2020.
Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16%.
Fourth quarter consolidated revenue was flat year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 7%.
Inivata Limited received the CE mark for its RaDaR™ assay in January 2022.
Inivata submitted to the MolDX program in the United States for the reimbursement of RaDaR™ for clinical testing.
Forward Guidance
The Company also issued 2022 guidance(3) today (in millions). GuidanceConsolidated revenue$530 - $550Net loss$(133) - $(118)Adjusted EBITDA$(40) - $(25)
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...